Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made one notable portfolio move on Monday, April 13. The ace hedge fund manager continued to cut exposure to Strata Critical Medical (SRTA), a healthcare logistics company focused on organ transplant transport services. The penny stock has gained 51% over the past year and closed 2% higher on Monday at $4.12 per share, while top analysts still see more than 120% upside from current levels.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
According to daily disclosures, ARK sold a total of 182,767 SRTA shares through its ARK Autonomous Technology & Robotics ETF (ARKQ) and ARK Space Exploration & Innovation ETF (ARKX), for a combined value of about $738,378.
The sale adds to a broader trend. ARK has been steadily reducing its position in SRTA over the past week, including a sale of more than 75,000 shares on April 10. The consistent selling of SRTA indicates that ARK may be reallocating capital toward higher-conviction growth plays within the genomics and robotics sectors.
Top Analysts Remain Upbeat about SRTA’s Growth Potential
Despite Cathie Wood’s reducing her stake, Wall Street analysts remain positive on the stock. Leading firms believe the market is currently underappreciating Strata’s unique position in the U.S. organ transplant market.
Recently, top B. Riley analyst Yuan Zhi initiated coverage of Strata Critical Medical with a Buy rating and an $8 price target. Zhi said the company operates one of the largest air transport and surgical service networks for transplant hospitals in the U.S. He noted that Strata is the only end-to-end platform in organ transplant logistics and is well-placed to benefit from long-term growth in the transplant market.
Similarly, 5-star analyst Bill Bonello of Craig-Hallum also initiated coverage with a Buy rating and the same $8 target. He said the company has made major changes over the past year, but its growth outlook is still not fully reflected in the stock. Bonello expects the valuation to improve as investors gain confidence in the company’s growth and see current estimates as conservative.
What Is the Future Outlook for SRTA?
On TipRanks, Wall Street has a Strong Buy consensus rating on Strata Critical Medical stock based on three unanimous Buy recommendations. Based on SRTA’s average price target of $9.08, top analysts see over 120% upside from current levels.
